Loading...

Ribomic

DB:1RI
Snowflake Description

Adequate balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1RI
DB
¥9B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Ribomic Inc., a biopharmaceutical venture company, develops molecular targeted pharmaceutical drugs using RNA aptamers in Japan. The last earnings update was 69 days ago. More info.


Add to Portfolio Compare Print
  • Ribomic has significant price volatility in the past 3 months.
1RI Share Price and Events
7 Day Returns
-3.8%
DB:1RI
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
9.1%
DB:1RI
-7.4%
DE Biotechs
-5.6%
DE Market
1RI Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Ribomic (1RI) -3.8% -15.1% 35.5% 9.1% -31.4% -
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • 1RI outperformed the Biotechs industry which returned -7.4% over the past year.
  • 1RI outperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
1RI
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Ribomic's competitors could be found in our database.

1RI Value

 Is Ribomic undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Ribomic. This is due to cash flow or dividend data being unavailable. The share price is €4.931.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Ribomic's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Ribomic's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1RI PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in JPY ¥-64.37
TSE:4591 Share Price ** TSE (2019-04-24) in JPY ¥656
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Ribomic.

DB:1RI PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSE:4591 Share Price ÷ EPS (both in JPY)

= 656 ÷ -64.37

-10.19x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ribomic is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Ribomic is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Ribomic's expected growth come at a high price?
Raw Data
DB:1RI PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -10.19x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-0.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Ribomic, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Ribomic's assets?
Raw Data
DB:1RI PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in JPY ¥113.55
TSE:4591 Share Price * TSE (2019-04-24) in JPY ¥656
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:1RI PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSE:4591 Share Price ÷ Book Value per Share (both in JPY)

= 656 ÷ 113.55

5.78x

* Primary Listing of Ribomic.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ribomic is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Ribomic's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Ribomic has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

1RI Future Performance

 How is Ribomic expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-0.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Ribomic expected to grow at an attractive rate?
  • Unable to compare Ribomic's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Ribomic's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Ribomic's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:1RI Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:1RI Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -0.6%
DB:1RI Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 84.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1RI Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in JPY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1RI Future Estimates Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-03-31 100 -890 -900 1
2020-03-31 100 -894 -900 1
2019-03-31 5 -839 -850 1
DB:1RI Past Financials Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income *
2018-12-31 14 -919
2018-09-30 30 -798 -904
2018-06-30 47 -867
2018-03-31 64 -694 -753
2017-12-31 68 -714
2017-09-30 77 -757 -700
2017-06-30 86 -661
2017-03-31 93 -706 -646
2016-12-31 101 -459
2016-09-30 103 -321 -393
2016-06-30 106 -371
2016-03-31 121 -324 -323

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Ribomic is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Ribomic's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1RI Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Ribomic Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1RI Future Estimates Data
Date (Data in JPY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-03-31 -62.50 -62.50 -62.50 1.00
2020-03-31 -62.50 -62.50 -62.50 1.00
2019-03-31 -59.40 -59.40 -59.40 1.00
DB:1RI Past Financials Data
Date (Data in JPY Millions) EPS *
2018-12-31 -64.37
2018-09-30 -64.37
2018-06-30 -62.85
2018-03-31 -55.60
2017-12-31 -53.44
2017-09-30 -52.58
2017-06-30 -49.81
2017-03-31 -48.79
2016-12-31 -34.80
2016-09-30 -29.95
2016-06-30 -28.43
2016-03-31 -24.90

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Ribomic will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Ribomic's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Ribomic has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

1RI Past Performance

  How has Ribomic performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Ribomic's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Ribomic does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Ribomic's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Ribomic's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Ribomic's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Ribomic Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1RI Past Revenue, Cash Flow and Net Income Data
Date (Data in JPY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 14.00 -919.00 324.00 748.00
2018-09-30 30.00 -904.00 315.00 759.00
2018-06-30 47.00 -867.00 307.00 746.00
2018-03-31 64.00 -753.00 300.00 663.00
2017-12-31 68.00 -714.00 285.00 604.00
2017-09-30 77.00 -700.00 283.00 621.00
2017-06-30 86.00 -661.00 282.00 599.00
2017-03-31 93.00 -646.00 268.00 610.00
2016-12-31 101.00 -459.00 254.00 521.00
2016-09-30 103.00 -393.00 241.00 453.00
2016-06-30 106.00 -371.00 225.00 455.00
2016-03-31 121.00 -323.00 219.00 435.00
2015-12-31 149.00 -365.00 217.00 334.00
2015-09-30 173.00 -317.00 213.00 313.00
2015-06-30 197.00 -286.00 213.00 291.00
2015-03-31 479.00 10.00 191.00 282.00
2014-03-31 151.00 -211.00 146.00 418.00
2013-03-31 168.00 -276.00 158.00 421.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Ribomic has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Ribomic has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Ribomic improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Ribomic's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Ribomic has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

1RI Health

 How is Ribomic's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Ribomic's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Ribomic is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Ribomic's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Ribomic's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Ribomic Company Filings, last reported 3 months ago.

DB:1RI Past Debt and Equity Data
Date (Data in JPY Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 1,634.00 1,000.00 2,636.00
2018-09-30 1,844.00 1,000.00 2,837.00
2018-06-30 2,038.00 1,000.00 3,028.00
2018-03-31 2,226.00 0.00 2,179.00
2017-12-31 2,007.00 0.00 1,928.00
2017-09-30 2,198.00 0.00 2,121.00
2017-06-30 2,284.00 0.00 2,231.00
2017-03-31 2,438.00 0.00 2,382.00
2016-12-31 2,631.00 0.00 2,650.00
2016-09-30 2,787.00 0.00 2,808.00
2016-06-30 2,908.00 0.00 2,943.00
2016-03-31 3,039.00 0.00 3,059.00
2015-12-31 3,017.00 0.00 2,986.00
2015-09-30 3,105.00 0.00 3,116.00
2015-06-30 3,191.00 0.00 3,226.00
2015-03-31 3,262.00 0.00 3,337.00
2014-03-31 353.00 0.00 330.00
2013-03-31 564.00 0.00 528.00
  • Ribomic's level of debt (61.2%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 61.2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Ribomic has sufficient cash runway for more than 3 years based on current free cash flow.
  • Ribomic has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 29.6% each year.
X
Financial health checks
We assess Ribomic's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Ribomic has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

1RI Dividends

 What is Ribomic's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Ribomic dividends.
If you bought €2,000 of Ribomic shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Ribomic's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Ribomic's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1RI Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1RI Future Dividends Estimate Data
Date (Data in ¥) Dividend per Share (annual) Avg. No. Analysts
2021-03-31
2020-03-31
2019-03-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Ribomic has not reported any payouts.
  • Unable to verify if Ribomic's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Ribomic's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Ribomic has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Ribomic's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Ribomic afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Ribomic has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

1RI Management

 What is the CEO of Ribomic's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Yoshikazu Nakamura
AGE 71
TENURE AS CEO 7.3 years
CEO Bio

Mr. Yoshikazu Nakamura, Ph.D. has been the President at Ribomic Inc. since April 2012 and has been its Chief Executive Officer since 2012. Mr. Nakamura has been a Representative Director at Ribomic Inc. October 2005. He has been Professor Emeritus at The University of Tokyo since June 2012. He is Assistant of Institute of Medical Science at University of Tokyo in April 1978.

CEO Compensation
  • Insufficient data for Yoshikazu to compare compensation growth.
  • Insufficient data for Yoshikazu to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Ribomic management team in years:

11.3
Average Tenure
67
Average Age
  • The average tenure for the Ribomic management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Yoshikazu Nakamura

TITLE
Chief Executive Officer
AGE
71
TENURE
7.3 yrs

Masayuki Miyazaki

TITLE
Executive Officer
AGE
67
TENURE
11.3 yrs

Kazuhiro Kawabata

TITLE
Chief of Audit Office

Masatoshi Fujiwara

TITLE
Executive Officer
AGE
58
TENURE
14.3 yrs
Board of Directors Tenure

Average tenure and age of the Ribomic board of directors in years:

8.8
Average Tenure
71
Average Age
  • The tenure for the Ribomic board of directors is about average.
Board of Directors

Yoshikazu Nakamura

TITLE
Chief Executive Officer
AGE
71
TENURE
13.5 yrs

Masayuki Miyazaki

TITLE
Executive Officer
AGE
67
TENURE
9.6 yrs

Masatoshi Fujiwara

TITLE
Executive Officer
AGE
58

Hirofumi Morikawa

TITLE
Independent Director
AGE
80
TENURE
3.8 yrs

Toshiaki Nishihata

TITLE
Independent Director
AGE
70
TENURE
3.3 yrs

Quan Nguyen

TITLE
Member of Scientific Advisory Board
TENURE
1.3 yrs

Karl Csaky

TITLE
Member of Scientific Advisory Board
TENURE
1.3 yrs

Motohiko Fujii

TITLE
Full-Time Independent Statutory Auditor
AGE
76
TENURE
8.8 yrs

Masaaki Takagi

TITLE
AGE
71
TENURE
11.6 yrs

Yutaka Yabe

TITLE
Outside Auditor
AGE
75
TENURE
8.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Ribomic's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Ribomic has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

1RI News

Simply Wall St News

1RI Company Info

Description

Ribomic Inc., a biopharmaceutical venture company, develops molecular targeted pharmaceutical drugs using RNA aptamers in Japan. It develops drugs in the areas of pain, sepsis, lung and other organ fibrosis, bone diseases, eye diseases, and inflammatory disorders. The company was founded in 2003 and is headquartered in Tokyo, Japan.

Details
Name: Ribomic Inc.
1RI
Exchange: DB
Founded: 2003
¥75,442,204
14,389,900
Website: http://www.ribomic.com
Address: Ribomic Inc.
3-16-13 Usui Building,
Shirokanedai,
Tokyo,
108-0071,
Japan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSE 4591 Common Shares The Tokyo Stock Exchange JP JPY 25. Sep 2014
DB 1RI Common Shares Deutsche Boerse AG DE EUR 25. Sep 2014
Number of employees
Current staff
Staff numbers
21
Ribomic employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 22:48
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/02/18
Last earnings filing: 2019/02/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.